NCT03680508View on ClinicalTrials.gov

TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2027

Conditions
Adult Primary Liver CancerAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer
Interventions
DRUG

TSR-022 and TSR-042

immunotherapy

Trial Locations (2)

96813

University of Hawaii, Honolulu

97239

Oregon Health & Science University Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Hawaii

OTHER